An observational study in Asthma, Mild-to-moderate Asthma and Asthma Control Level, sponsored by Thammasat University. Recruiting at 2 sites in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by Thammasat University · Observational
The goal of this observational study is to determine the prevalence of remission among adults with mild-to-moderate asthma, as well as the factors associated with remission in Thailand.
The main question the study aims to answer is:
What is the prevalence of remission among adults with severe asthma in Thailand? Participants will complete a questionnaire on asthma symptoms and undergo pulmonary function testing and a blood test once.
This study is a cross-sectional study. Thai patients aged 18 years or older with mild-to-moderate asthma are included in the study. Participants will complete two questionnaires about asthma control: the Global Initiative for Asthma (GINA) and the Asthma Control Test (ACT), and will perform spirometry, a fractional exhaled nitric oxide (FeNO) test, and blood eosinophil counts (BEC).
GINA and ACT are questionnaires used to assess the level of asthma control.
3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.
This study's planned enrollment of 289 is above the median of 150 across 970 observational studies indexed under Asthma.
Browse Asthma studies →Thammasat University is the lead sponsor of 83 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Thai patients aged 18 years or older with mild-to-moderate asthma are included in the study
Exclusion Criteria:
Patients aged 18 years or older with mild-to-moderate asthma. Mild asthma refers to asthma patients who experience symptoms \<3 times per week, have preserved lung function (FEV₁ or PEF \>80% of predicted), and whose symptoms can be adequately controlled with low-dose inhaled corticosteroids (low-dose ICS) alone, without the need for long-acting bronchodilators or other controller medications. Moderate asthma refers to asthma patients who have symptoms \>4-5 days per week or experience nocturnal asthma symptoms \>1 per week, and who require treatment with medium-dose inhaled corticosteroids (medium-dose ICS) or low-dose ICS in combination with a long-acting β₂-agonist (low-dose ICS/LABA) to achieve symptom control and prevent exacerbations.
Other: Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires · Other: Spirometry · Other: Fractional exhaled nitric oxide (FeNO) test · Other: Blood eosinophil count (BEC)
GINA and ACT are questionnaires used to assess the level of asthma control.
Spirometry is a tool used to assess pulmonary function.
FeNO is a tool used to assess eosinophilic airway inflammation and asthma remission.
BEC is a tool used to assess eosinophilic inflammation and asthma remission.
Prevalence rate of mild-to-moderate asthma remission
Prevalence rate of mild-to-moderate asthma remission (%)
Time frame: An average of 1 year
Asthma control in patients with mild-to-moderate asthma
Rate of patients with well-controlled asthma. Well-controlled asthma is defined as an Asthma Control Test (ACT) score of 20 or higher.
Time frame: At baseline and at 12 months
Airway obstruction in patients with mild-to-moderate asthma
Airway obstruction is assessed using FEV1/FVC ratio on spirometry.
Time frame: At baseline and at 12 months
Severity of aiway obstruction in patients with mild-to-moderate asthma
The severity of aiway obstruction is assessed using FEV1 % predicted on spirometry.
Time frame: At baseline and at 12 months
Eosinophil airway inflammation in patients with mild-to-moderate asthma
Eosinophil airway inflammation is assessed using blood eosinophil count (cells/µL).
Time frame: At baseline and at 12 months
Type 2 airway inflammation in patients with mild-to-moderate asthma
Type 2 airway inflammation is assessed using fractional exhaled nitric oxide (FeNO, ppb).
Time frame: At baseline and at 12 months
Plan to share: Yes — IPD and documents will be available for sharing immediately after publication for a period of 2 years.
Supporting information: Study protocol, Sap
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Thammasat University